Vizsgálati helyszín

Polyclinique De Limoges

Limoges Cedex I, 87039, FranciaországMég nincs intézményhez kötve

27futó vizsgálat
3lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 30 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Vesedaganat7 vizsgálat
Áttétes emlőrák6 vizsgálat
Hólyagrák5 vizsgálat
Prosztatarák5 vizsgálat
Tüdőrák5 vizsgálat
Vastagbélrák4 vizsgálat
Fej-nyaki daganatok2 vizsgálat
Gyomor- és nyelőcsőrák2 vizsgálat
Máj- és epeúti rák2 vizsgálat
Méhtestrák2 vizsgálat
Melanóma2 vizsgálat
Tripla negatív emlőrák2 vizsgálat
és még 5
Fázis: 3. fázis23 vizsgálat
2. fázis7 vizsgálat
Állapot: Fut, nem toboroz16 vizsgálat
Toboroz11 vizsgálat
Lezárult3 vizsgálat
Fő szponzor: UNICANCER7 vizsgálat
Merck Sharp & Dohme LLC6 vizsgálat
Unicancer3 vizsgálat
Janssen Research & Development, LLC2 vizsgálat
University Hospital, Bordeaux2 vizsgálat
és még 10

Futó vizsgálatok

Toboroz
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
2025-524160-38-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· UNICANCER· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.
2023-507684-19-00· 3. fázis· Janssen Cilag International· Forrás
Fut, nem toboroz
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients with Breast Cancer
NCT06112379· 3. fázis· Astrazeneca AB· Forrás
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337· 3. fázis· DualityBio Inc.· Forrás
Fut, nem toboroz
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT05617963· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318· 3. fázis· University Hospital, Bordeaux· Forrás
Fut, nem toboroz
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· 2. fázis· Unicancer· Forrás
Fut, nem toboroz
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
NCT05078047· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· 3. fázis· University Hospital, Bordeaux· Forrás
Fut, nem toboroz
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.
NCT04158362· 3. fázis· Unicancer· Forrás
Fut, nem toboroz
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
NCT04181203· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
NCT04053322· 2. fázis· UNICANCER· Forrás
Toboroz
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
NCT03819101· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer
2024-512173-27-00· 3. fázis· Unicancer· Forrás
Fut, nem toboroz
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Lezárult
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Fut, nem toboroz
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
NCT04436640· 3. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643· 3. fázis· Merck Sharp & Dohme LLC· Forrás

Helyszínadatok: EU CTIS (euclinicaltrials.eu)Frissítve: 2026. nov. 12.

Hibát jelzek